12-Jan-2026 6:00 AM CST - Business Wire TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and ful
4-Dec-2025 3:01 PM CST - Business Wire TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cur
13-Nov-2025 3:01 PM CST - Business Wire TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinica
11-Nov-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Participate in Upcoming Investor Conferences TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Canaccord Genuity MedTech, Diagnostics and Digital Health
30-Oct-2025 7:00 AM CST - Business Wire TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss
28-Aug-2025 7:00 AM CST - Business Wire TriSalus Life Sciences to Participate in Upcoming September Investor Conferences TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the foll
12-Aug-2025 3:01 PM CST - Business Wire TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical ado
30-Jul-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings dur
29-Jul-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. A press release detailing the results will b
12-Jan-2026 6:00 AM CST - Business Wire TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and ful
4-Dec-2025 3:01 PM CST - Business Wire TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cur
13-Nov-2025 3:01 PM CST - Business Wire TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinica
11-Nov-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Participate in Upcoming Investor Conferences TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Canaccord Genuity MedTech, Diagnostics and Digital Health
30-Oct-2025 7:00 AM CST - Business Wire TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss
28-Aug-2025 7:00 AM CST - Business Wire TriSalus Life Sciences to Participate in Upcoming September Investor Conferences TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the foll
12-Aug-2025 3:01 PM CST - Business Wire TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical ado
30-Jul-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings dur
29-Jul-2025 3:05 PM CST - Business Wire TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. A press release detailing the results will b
